STOCK TITAN

Revvity Inc. - RVTY STOCK NEWS

Welcome to our dedicated news page for Revvity (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revvity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revvity's position in the market.

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals ClinicalTM, a centralized data science platform integrated with Spotfire for efficient clinical study data management, enabling quick clinical decisions and therapeutic advancements. The platform emphasizes cross-functional collaboration, customization, and scalability to enhance clinical research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
clinical trial
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) reported a 6% decline in fourth quarter revenue, with a GAAP EPS of $0.64 and adjusted EPS of $1.25. The full year 2023 saw a 17% decrease in revenue and a 59% decrease in GAAP EPS compared to 2022. The company initiated full year 2024 guidance of $2.79-$2.85 billion in revenue and adjusted EPS of $4.55-$4.75. The life sciences segment experienced an 8% decrease in revenue for Q4 2023, while the diagnostics segment saw a 4% decrease. The company's financial performance reflects a challenging year and uncertain future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
earnings
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) announced the election of Sophie Vandebroek and Michael Klobuchar to its board of directors, effective February 1, 2024. Vandebroek brings expertise in AI, business processes, sustainability, and cybersecurity, with a background in global organizations and academic advisory. Klobuchar, an executive at Merck & Co. Inc., has extensive experience in strategic and operational initiatives for global enterprises, M&A activities, and leadership in research and development. The company also expressed gratitude to Dr. Sylvie Gregoire for her service on the board since 2015.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
management
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) has announced a regular quarterly dividend of $0.07 per share of common stock, payable on May 10, 2024, to shareholders of record at the close of business on April 19, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
dividends
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) announces Q4 2023 financial results, including a revenue decline of -7% and -4% in organic revenue. Full year 2023 adjusted earnings per share expected to meet or exceed guidance. Prahlad Singh to present at J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
earnings
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference to provide an update on the Company and its strategic priorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
conferences
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) to Present at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
conferences
-
Rhea-AI Summary
Revvity, Inc. reported Q3 2023 financial results with $671 million in revenue, representing a 6% decrease. GAAP EPS was $0.08, compared to $0.67 in the same period last year. Adjusted EPS from continuing operations was $1.18. The company updated its full year 2023 guidance with a forecasted revenue of $2.72-$2.74 billion and adjusted EPS of $4.53-$4.57.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
earnings
-
Rhea-AI Summary
Revvity (NYSE: RVTY) declares regular quarterly dividend of $0.07 per share of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
dividends
News
Rhea-AI Summary
Revvity, Inc. unveils its inaugural 2023 ESG Report, highlighting its commitment to sustainability and transparency. Key goals include reducing greenhouse gas emissions by 50% by 2033, achieving net carbon neutrality by 2040, and maintaining greater than 40% female representation in leadership positions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
Revvity Inc.

NYSE:RVTY

RVTY Rankings

RVTY Stock Data

12.59B
111.57M
0.27%
88.18%
3.23%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
Boston

About RVTY

as a leader focused on improving human and environmental health, we are helping scientists, clinicians, and government agencies discover more effective diagnostics and therapies, and making sure that the food we eat and the air we breathe are safe from contaminants. environmental health overview at perkinelmer, we’re taking action to ensure the quality of our environment. the ability to rapidly detect known and unknown contaminants in our food, water and air, or to monitor their quality consistently, is an important part of maintaining a healthy environment. our systems and services help scientists understand all of these complexities and ensure compliance. from food safety to air & water quality, perkinelmer transforms information into results that improve our health and safety today and our world tomorrow. human health overview perkinelmer creates life science research and diagnostic instrumentation as well as informatics and diagnostic lab services—all to fight illness proacti